DYAI

Rating neutralTentativeAI Memo

Dyadic International

As of 2026-09-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Conversion of pilot sales into repeat orders • 2026-12-31

Base target: $0 / p=45% prob

Biggest risk

Q2 revenue was roughly flat year over year at $0.96 million, largely grant-funded, while operating loss rose to $2.05 million. Continued cash use, dilution, or weak order conversion could outweigh platform progress [#SEC-8K-2026-08-12]. Q2 earnings exhibit.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Pilot sales become repeat orders, partner products generate royalties, and funded programs validate C1 without heavy incremental spending.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-24

Base target

p=45%

Bull target

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Financing and runway
Funded antibody-program preclinical progress
Partner-led royalties and licensing

BearKey bullets

Management reported substantial doubt about Dyadic's ability to continue as a going concern; first-half operating cash use was $3.78 million [#SEC-10Q-2026-08-12].
Quarterly filing.
Preclinical programs face technical, funding, and eventual regulatory uncertainty.

WatchKey bullets

Conversion of pilot sales into repeat orders

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=45%)

Target spread vs base: +74% / -44%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=45%)Bear Target: $0 (p=35%)

Commentary

Coverage in the packet is concentrated around the August Q2 results. Company-reported commercialization progress is constructive, but flat quarterly revenue and going-concern doubt temper it. Reliable social, options, short-interest, employee-rating, analyst-revision, and post-release price-reaction data were unavailable; zero sentiment fields denote missing data, not neutral readings. The deterministic directional prior is neutral, and no material thesis change is established.

As of 2026-09-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Pilot sales become repeat orders, partner products generate royalties, and funded programs validate C1 without heavy incremental spending.

Bear Case

Drivers

Scannable catalysts and supporting factors

Financing and runway
Funded antibody-program preclinical progress
Partner-led royalties and licensing

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=45% prob

Bear Target (Scenario probability)

$0 / p=35% prob

Analysis 2026-09-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Conversion of pilot sales into repeat orders
Dyadic reported shipments of six recombinant protein products after quarter-end and initial pilot sales, but repeat-order economics remain unproven. Sustained purchasing through customers and distribution partners would be stronger evidence of commercialization than shipments alone [#SEC-8K-2026-08-12]. Q2 earnings exhibit.
Prob 50.00% • Move 30.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Financing and runway
2026-12-31
Dyadic agreed in August to sell 3.625 million shares and warrants for another 3.625 million shares, for approximately $2.9 million in expected gross proceeds. The cited filing said closing was expected, not completed. Confirmation of proceeds and the subsequent cash runway matter because management reported substantial going-concern doubt [#8-K-2026-08-14] [#SEC-10Q-2026-08-12]. Offering filing; quarterly filing.
Prob 70% • Move -20% • Priced-in 65%

Long-term Catalysts

Months to a year

Funded antibody-program preclinical progress
2027-06-30
Dyadic said it was working toward delivering C1-produced RSV or malaria antibody material to support preclinical studies. Delivery and subsequent results could validate the platform, but no trial-readout date or clinical outcome was established [#SEC-8K-2026-08-12]. Q2 earnings exhibit.
Prob 40% • Move 25% • Priced-in 10%
Partner-led royalties and licensing
2027-09-30
Proliant began commercializing Albufree DX, while other partner products remain at initial-sales or development stages. Material royalties or milestones would test whether partner activity can become meaningful revenue; timing and scale are not established [#SEC-8K-2026-08-12]. Q2 earnings exhibit.
Prob 35% • Move 55% • Priced-in 15%

Risks

Management reported substantial doubt about Dyadic's ability to continue as a going concern; first-half operating cash use was $3.78 million [#SEC-10Q-2026-08-12]. Quarterly filing.
Preclinical programs face technical, funding, and eventual regulatory uncertainty.
Product qualification and initial sales may not convert into repeat orders or meaningful royalties.
The August share-and-warrant financing creates dilution and warrant overhang; completion is not confirmed by the cited filing [#8-K-2026-08-14]. Offering filing.

Peers

Symbol	Summary
CDXS	Adjacent platform comparator: Codexis engineers enzymes for pharmaceutical biocatalysis, RNA manufacturing, and diagnostics. The enzyme-engineering overlap is real, but its therapeutic-manufacturing focus differs from Dyadic's recombinant-protein and food applications. Codexis investor overview.
TECH	Direct cell-culture input comparator: Bio-Techne manufactures animal-free recombinant proteins, growth factors, and cytokines for research and cell-therapy workflows, overlapping Dyadic's targeted product uses. Its established manufacturing footprint and much greater scale make it an operating benchmark, not a valuation twin. Bio-Techne protein portfolio; company release.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-24